Report
EUR 13.91 For Business Accounts Only

A double requalification allows SUNDRUG to improve to Slightly Positive

SUNDRUG (JP), a company active in the Drug Retailers industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 3 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date January 25, 2022, the closing price was JPY 2,923.00 and its potential was estimated at JPY 3,394.18.
Underlying
Sundrug Co. Ltd.

Sundrug is mainly engaged in the operation of drugstore chain throughout Japan. Co. operates in two business segments. The Drugstore segment operates the drugstore chains such as “Sundrug,” “Sundrug Pharmacies,” “Drug Tops,” “Seikoudou Yakkyoku,” and “Sundrug Plus.” These drugstores sell pharmaceuticals, cosmetics, and household products. The Discount store segment is engaged in the operation of discount stores selling foods and household products under the name of "Direx." As of Mar 31 2017, Co. operates 831 drugstores including franchise stores, and 239 discount stores.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch